US 11,680,061 B2
Crystal forms C and E of pyrazin-2(1H)-one compound and preparation method therefor
Fei Hong, Zhangzhou (CN); Jinming Huang, Zhangzhou (CN); Longhui Gao, Zhangzhou (CN); Shicong Wang, Zhangzhou (CN); Tingting Yin, Zhangzhou (CN); Zhifei Fu, Shanghai (CN); Miaorong Luo, Shanghai (CN); Yang Zhang, Shanghai (CN); Jian Li, Shanghai (CN); and Shuhui Chen, Shanghai (CN)
Assigned to ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD., Fujian (CN)
Appl. No. 17/633,319
Filed by ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD., Fujian (CN)
PCT Filed Aug. 4, 2020, PCT No. PCT/CN2020/106896
§ 371(c)(1), (2) Date Feb. 7, 2022,
PCT Pub. No. WO2021/023194, PCT Pub. Date Feb. 11, 2021.
Claims priority of application No. 201910731661.4 (CN), filed on Aug. 8, 2019; and application No. 201911059969.5 (CN), filed on Nov. 1, 2019.
Prior Publication US 2022/0289722 A1, Sep. 15, 2022
Int. Cl. C07D 403/14 (2006.01)
CPC C07D 403/14 (2013.01) [C07B 2200/13 (2013.01)] 14 Claims
 
1. A crystal form C of the hydrochloride salt as shown in formula (II), wherein the crystal form C has an X-ray powder diffraction pattern comprising characteristic diffraction peaks at the following 2θ angles: 5.24±0.20°, 9.58±0.20°, 10.45±0.20°, 14.26±0.20°, 20.86±0.20°, 24.99±0.20°, 26.21±0.20° and 27.71±0.20°,

OG Complex Work Unit Chemistry